Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Integra Lifesciences Holdings (IART) Revenue (2016 - 2026)

Integra Lifesciences Holdings' Revenue history spans 17 years, with the latest figure at $434.9 million for Q4 2025.

  • On a quarterly basis, Revenue fell 1.74% to $434.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.6 billion, a 1.53% increase, with the full-year FY2025 number at $1.6 billion, up 1.53% from a year prior.
  • Revenue hit $434.9 million in Q4 2025 for Integra Lifesciences Holdings, up from $402.1 million in the prior quarter.
  • Over the last five years, Revenue for IART hit a ceiling of $442.6 million in Q4 2024 and a floor of $360.1 million in Q1 2021.
  • Historically, Revenue has averaged $394.4 million across 5 years, with a median of $388.4 million in 2021.
  • Biggest five-year swings in Revenue: soared 50.77% in 2021 and later decreased 4.16% in 2023.
  • Tracing IART's Revenue over 5 years: stood at $405.5 million in 2021, then fell by 1.85% to $398.0 million in 2022, then fell by 0.25% to $397.0 million in 2023, then grew by 11.49% to $442.6 million in 2024, then decreased by 1.74% to $434.9 million in 2025.
  • Business Quant data shows Revenue for IART at $434.9 million in Q4 2025, $402.1 million in Q3 2025, and $415.6 million in Q2 2025.